GPLD1 and prostate carcinoma: As previously mentioned, catechin and Res synergically inhibit SphK1 activity, via a novel ERK/PLD-dependent mechanism in prostate cancer cells (C4-2B hormone-responsive and PC-3 hormone- refractory) acting as a possible anti-cancer effector [40].